Purchase this article with an account.
Masaki Shibata, Yutaka Imamura, Asuka Takeyama, Rieko Kato, Masahiro Ishida; Very early effects of intravitreal aflibercept and bevacizumab injections for retinal vein occlusion: comparison of 2 drugs. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4273.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate functional and anatomical effects of intravitreal aflibercept (IVA) and bevacizumab (IVB) injections for retinal vein occlusion, and possible differences between 2 drugs very shortly after treatment.
LogMAR visual acuity, central macular thickness and subfoveal choroidal thickness in patients with retinal vein occlusion undergoing either alibercept or bevacizumab injection were retrospectively analysed. Changes of the parameters at 1 day and 1 week after injection were compared between IVA and IVB groups.
There were 42 eyes of 42 patients (22 females, mean age: 68.7 years) including 42 eyes with retinal vein occlusions, which had not been treated previously. The change rates of central retinal thickness of IVA group (N=18) and IVB group (N=24) were 55.17±15.01% and 75.85±15.78% at 1day after injection (unpaired t test, P<0.001) and 40.52±15.46% and 46.58±23.96% at 1 week (P=0.451) respectively. The change rates of subfoveal choroidal thicknesses of IVA and IVB were 91.18±15.74% and 101.20±9.67% (P=0.022) at 1day and 84.07±14.13% and 96.11±6.39% (P=0.016) at 1 week, respectively. Changes of LogMAR visual acuity were not different between the 2 groups (P=0.715 at 1day and P=0.095 at 1 week).
Aflibercept appears to make retina and choroid thinner than bevacizumab shortly after injection, whose long-term significance for functional outcomes remains to be elucidated.
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.
This PDF is available to Subscribers Only